See more : Revelstone Capital Acquisition Corp. (RCAC) Income Statement Analysis – Financial Results
Complete financial analysis of Bellicum Pharmaceuticals, Inc. (BLCM) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Bellicum Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ram Ratna Wires Limited (RAMRAT.BO) Income Statement Analysis – Financial Results
- Healthcare AI Acquisition Corp. (HAIA) Income Statement Analysis – Financial Results
- NGL Energy Partners LP (NGL-PB) Income Statement Analysis – Financial Results
- EBR Systems, Inc. (EBR.AX) Income Statement Analysis – Financial Results
- Medartis Holding AG (MED.SW) Income Statement Analysis – Financial Results
Bellicum Pharmaceuticals, Inc. (BLCM)
About Bellicum Pharmaceuticals, Inc.
Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 1.50M | 6.20M | 500.00K | 7.14M | 1.12M | 185.00K | 388.00K | 282.00K | 1.78M | 1.94M | 1.47M |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 22.76M | 23.58M | 39.05M | 64.54M | 71.15M | 65.66M | 51.26M | 33.56M | 11.01M | 7.05M | 5.80M |
| General & Administrative | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.72M | 7.01M | 15.53M | 29.97M | 25.43M | 21.91M | 17.51M | 15.86M | 5.40M | 2.81M | 1.94M |
| Other Expenses | 0.00 | 7.00K | 112.00K | -2.99M | 436.00K | 864.00K | 580.00K | 3.18M | 43.21B | 0.00 | 0.00 |
| Operating Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Cost & Expenses | 28.48M | 30.59M | 54.58M | 94.51M | 96.59M | 87.57M | 68.77M | 49.42M | 16.41M | 9.86M | 7.74M |
| Interest Income | 0.00 | 32.00K | 387.00K | 1.35M | 1.64M | 1.06M | 909.00K | 641.00K | 34.98K | 3.92K | 7.55K |
| Interest Expense | 46.00 | 4.00K | 2.66M | 4.28M | 4.20M | 3.67M | 1.76M | 12.00K | 1.76M | 50.72K | 1.41K |
| Depreciation & Amortization | -1.95M | 517.00K | -1.89M | 19.19M | 6.70M | 3.56M | 2.31M | 1.20M | 666.61K | 587.25K | 115.28K |
| EBITDA | -26.98M | -24.35M | 2.39M | -87.36M | -95.47M | -82.77M | -68.38M | -47.30M | -57.84B | -7.33M | -6.15M |
| EBITDA Ratio | -1,928.93% | -392.73% | -10,716.80% | -954.39% | -8,523.75% | -44,739.46% | -17,623.71% | -16,771.28% | -821.69% | -377.75% | -418.02% |
| Operating Income | -26.98M | -24.87M | -51.69M | -87.36M | -95.47M | -87.39M | -68.38M | -49.14M | -57.84M | -7.92M | -6.27M |
| Operating Income Ratio | -1,798.73% | -401.06% | -10,338.40% | -1,223.07% | -8,523.75% | -47,236.22% | -17,623.71% | -17,423.76% | -3,249.33% | -408.21% | -426.37% |
| Total Other Income/Expenses | 2.01M | 15.16M | -10.11M | -25.11M | -2.57M | -4.39M | -861.00K | 587.00K | -26.13M | -46.80K | 6.14K |
| Income Before Tax | -24.97M | -9.71M | -7.72M | -112.48M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Income Before Tax Ratio | -1,664.73% | -156.53% | -1,544.40% | -1,574.65% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| Income Tax Expense | 2.00K | -127.00K | 897.00K | 13.62M | 1.63M | 3.67M | -1.46M | 12.00K | 1.09M | 3.92K | 7.55K |
| Net Income | -24.97M | -9.58M | -8.62M | -126.09M | -98.04M | -91.78M | -69.24M | -48.55M | -83.97M | -7.97M | -6.26M |
| Net Income Ratio | -1,664.87% | -154.48% | -1,723.80% | -1,765.25% | -8,753.21% | -49,610.27% | -17,845.62% | -17,215.60% | -4,717.13% | -410.62% | -425.96% |
| EPS | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| EPS Diluted | -0.81 | -0.83 | -1.50 | -26.92 | -24.37 | -28.94 | -25.69 | -18.43 | -33.47 | -8.11 | -6.37 |
| Weighted Avg Shares Out | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
| Weighted Avg Shares Out (Dil) | 30.83M | 11.50M | 5.76M | 4.68M | 4.02M | 3.17M | 2.70M | 2.63M | 2.51M | 982.78K | 982.78K |
INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 from Investment in Bellicum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit
BLCM LOSS NOTICE: Rosen Law Firm Reminds Bellicum Pharmaceuticals, Inc. Investors of Important Deadline in Class Action – BLCM
Robbins Arroyo LLP: Bellicum Pharmaceuticals, Inc. (BLCM) Misled Shareholders According to a Recently Filed Class Action
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Bellicum Pharmaceuticals, Inc. – BLCM
Source: https://incomestatements.info
Category: Stock Reports